FDA Approves First US Biosimilar; Hold Your Breath On Cost Savings
The long-anticipated approval of the first biosimilar drug ? a sort of generic biotechnology drug ? occurred this morning. The FDA approved Sandoz's version of the white blood cell growth hormone, filgrastim, the analog of Amgen's Neupogen. But after all of this effort, will it really be less expensive? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 6, 2015 Category: Pharmaceuticals Authors: David Kroll Source Type: news
First Biosimilar Approved in US: Filgrastim-sndz (Zarxio)First Biosimilar Approved in US: Filgrastim-sndz (Zarxio)
The first biosimilar product approved in the United States is filgrastim-sndz (Zarxio, Sandoz/Novartis), which was found to be similar to Amgen's Neupogen. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves first biosimilar product Zarxio
The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the U.S. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news
Biosimilars: More Treatment Options Are on the Way
The Food and Drug Administration (FDA) is approving Zarxio (filgrastim-sndz), the first biosimilar product (or biosimilar), and expects to approve others in the months ahead. What are biosimilars? How will they affect patient treatment? (Source: FDA Consumer Updates)
Source: FDA Consumer Updates - March 6, 2015 Category: Consumer Health News Source Type: news
Accord Healthcare launches their first biopharmaceutical product in Europe: Accofil® (filgrastim)
Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 29, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cost effectiveness Industry News Haematology Oncology biopharmaceutical chemotherapy induced neutropenia filgrastim hiv Latest News peripheral blood progenitor cells Source Type: news
Granix (Tbo-filgrastim Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 9, 2015 Category: Drugs & Pharmacology Source Type: news
Biosimilar Filgrastim Recommended for Approval in US Biosimilar Filgrastim Recommended for Approval in US
A biosimilar filgrastim (Novartis) has been recommended for approval in the US, after it was found not clinically different from Amgen's Neupogen. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Why The FDA Panel's Nod To Sandoz's Filgrastim (Zarzio) Is Good News For Patients
The implications extend beyond cancer drugs. Biosimilars have the potential to significantly reduce the costs of modern health care for people with all kinds of illness (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 7, 2015 Category: Pharmaceuticals Authors: Elaine Schattner Source Type: news
FDA Panel to Consider Biosimilar for Filgrastim
(MedPage Today) -- FDA staff are strongly supportive in pre-meeting report. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 7, 2015 Category: Primary Care Source Type: news
FDA Expands Indication for Tbo-filgrastimFDA Expands Indication for Tbo-filgrastim
The granulocyte colony-stimulating factor analog can now be self-administered by patients, with the new expanded FDA indication. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
What’s the Difference Between Neulasta...
Chemotherapy can cause your neutrophil counts to drop, which puts you at risk of infection. Neutropenia is treated with Neulasta or Neupogen, but what's the difference, and how do you choose? Read more to understand your choices. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - December 25, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
FDA OKs 1st Biosimilar to Prevent Chemo - Related Infections
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Infections, Internal Medicine, Oncology, Pharmacy, Institutional, Source Type: news
CHMP Gives Nod to New Drugs in Cancer CareCHMP Gives Nod to New Drugs in Cancer Care
Marketing authorization has been granted in Europe for generic versions of busulfan and filgrastim and for expanded use of denosumab. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
U.S. paves way for Novartis to copy Amgen biotech drug
(Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Pegfilgrastim-Induced Pain in Patients With LymphomaPegfilgrastim-Induced Pain in Patients With Lymphoma
Growth factors, such as pegfilgrastim or filgrastim, have reduced the incidence, duration, and severity of chemotherapy-related neutropenia, but what are the common side effects? Oncology Nursing Forum (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2014 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news
